GRI Bio, Inc.

Contributing Author

Recent Articles by GRI Bio, Inc.

Feb-05	GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial GRI -17.05% GlobeNewswire
Feb-04	GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights GRI GlobeNewswire
Jan-28	GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF GRI -22.74% GlobeNewswire
Jan-26	GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures GRI GlobeNewswire
Jan-21	GRI Bio Announces Reverse Stock Split GRI -12.02% GRI GlobeNewswire
Jan-08	GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 GRI GlobeNewswire
Dec-12	GRI Bio Announces Closing of $8.0 Million Public Offering GRI -10.04% GRI GlobeNewswire
Dec-11	GRI Bio Announces Pricing of $8,000,000 Million Public Offering GRI -56.45% GlobeNewswire
Dec-10	GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI -12.95% GlobeNewswire
Sep-11	GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI +31.41% GlobeNewswire
Sep-03	GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference GRI GlobeNewswire
Aug-14	GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech GRI +10.77% GlobeNewswire
Jul-31	GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment GRI -37.56% GlobeNewswire
Jul-31	GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI -37.56% GlobeNewswire
Jul-22	GRI Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference GRI GlobeNewswire
Jul-01	GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") GRI +6.20% GlobeNewswire
Jun-26	GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI -5.19% GlobeNewswire
May-22	GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results GRI -9.42% GlobeNewswire
May-21	GRI Bio to Participate in the Virtual Investor Closing Bell Series GRI GlobeNewswire
May-16	GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase GRI GlobeNewswire
May-15	GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 GRI GlobeNewswire
May-08	GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI -10.61% GlobeNewswire
May-07	GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") GRI -6.28% GlobeNewswire

GRI Bio, Inc.

Recent Articles by GRI Bio, Inc.

Upgrade your FINVIZ experience